Want to see FR:SIGHT full AI Analyst Report?
SIGHT Stock Chart & Stats
€0.08
>-€0.01(-0.18%)
At close: 4:00 PM EST
€0.08
>-€0.01(-0.18%)
Day’s Range― - ―
52-Week Range€0.08 - €0.24
Previous CloseN/A
Volume2.06K
Average Volume (3M)616.46K
Market Cap
€19.29M
Enterprise Value€23.78M
Total Cash (Recent Filing)€2.42M
Total Debt (Recent Filing)€12.86M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding235,044,330
10 Day Avg. Volume718,774
30 Day Avg. Volume616,456
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€5.50M
Bulls Say, Bears Say
Bulls Say
Focused Gene-therapy PipelineGenSight's specialization in gene therapies for severe retinal and neuro-ophthalmic diseases targets high unmet medical need and niche markets. That focused R&D strategy supports durable IP value, potential regulatory incentives, and long development timelines that can create lasting franchise value if clinical milestones are met.
Reduced Debt Level In 2025Leverage fell to roughly €12.9M in 2025, a structural improvement versus prior years. Lower debt reduces refinancing and interest pressure, improves solvency headroom and financial flexibility, and meaningfully extends the firm's ability to fund trials or partner programs without immediate distress financing.
Improving Operating Cash BurnOperating cash outflows narrowed in 2025 relative to 2024, indicating better cash discipline or lowered spend. A sustained decline in cash burn materially reduces near-term funding needs, lowers dilution risk from financing rounds, and supports continuity of multi-year development programs.
Bears Say
Revenue Collapse In 2025Revenue fell almost entirely in 2025, showing no commercial scale or stable sales base. This destroys internal funding capacity, raises execution risk for costly development programs, and forces reliance on external capital or partnerships to sustain operations and progress clinical assets.
Negative Shareholders' Equity Since 2022Persistently negative equity is a structural solvency concern that constrains capital-raising flexibility and creditor confidence. Over time it tends to necessitate dilutive equity issuances or expensive financing, weakening long-term ownership economics and corporate stability.
Chronic Operating Cash BurnOperating cash flow has been negative annually, signaling ongoing cash burn despite some improvement. Sustained negative cash generation forces repeated external funding, increases dilution risk, and creates uncertainty about uninterrupted financing for multi-year R&D programs and late-stage development needs.
GenSight Biologics SA News
SIGHT FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.07 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €19.29M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Sep 29, 2026 which is in 77 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Mar 27, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.027.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently Overvalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 235,044,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.409%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in FR:SIGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Technical Analysis
Options Prices
Currently, No data available
---